195 related articles for article (PubMed ID: 37300337)
1. A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections.
Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H
Mycoses; 2023 Sep; 66(9):815-824. PubMed ID: 37300337
[TBL] [Abstract][Full Text] [Related]
2. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
[TBL] [Abstract][Full Text] [Related]
3. Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients.
Samanta P; Clancy CJ; Marini RV; Rivosecchi RM; McCreary EK; Shields RK; Falcione BA; Viehman A; Sacha L; Kwak EJ; Silveira FP; Sanchez PG; Morrell M; Clarke L; Nguyen MH
Clin Infect Dis; 2021 Aug; 73(3):416-426. PubMed ID: 32463873
[TBL] [Abstract][Full Text] [Related]
4. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
Stern A; Su Y; Lee YJ; Seo S; Shaffer B; Tamari R; Gyurkocza B; Barker J; Bogler Y; Giralt S; Perales MA; Papanicolaou GA
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1195-1202. PubMed ID: 32088367
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting.
Ping Y; Hongmei J; Bellmann C; Inês M; Macmillan T; Webb N; Aram JA; Penack O
Hematology; 2022 Dec; 27(1):723-732. PubMed ID: 35688453
[TBL] [Abstract][Full Text] [Related]
6. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Bogler Y; Stern A; Su Y; Lee YJ; Seo SK; Shaffer B; Perales MA; Papanicolaou GA; Neofytos D
Med Mycol; 2021 Oct; 59(10):970-979. PubMed ID: 34036319
[TBL] [Abstract][Full Text] [Related]
8. Network meta-analysis of triazole, polyene, and echinocandin antifungal agents in invasive fungal infection prophylaxis in patients with hematological malignancies.
Zeng H; Wu Z; Yu B; Wang B; Wu C; Wu J; Lai J; Gao X; Chen J
BMC Cancer; 2021 Apr; 21(1):404. PubMed ID: 33853560
[TBL] [Abstract][Full Text] [Related]
9. Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia.
White O; Kennedy E; Huckabee JB; Rogers E; LeBlanc TW; Dillon M; Li Z; Hanna D
J Oncol Pharm Pract; 2024 Apr; 30(3):527-534. PubMed ID: 37186784
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
[TBL] [Abstract][Full Text] [Related]
11. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.
Van Matre ET; Evans SL; Mueller SW; MacLaren R; Fish DN; Kiser TH
Ann Clin Microbiol Antimicrob; 2019 Mar; 18(1):13. PubMed ID: 30894179
[TBL] [Abstract][Full Text] [Related]
13. Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological Malignancies.
Gatti M; Campoli C; Belotti T; Cojutti PG; Masetti R; Pession A; Viale P; Pea F
Ther Drug Monit; 2022 Oct; 44(5):641-650. PubMed ID: 35344524
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ
Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016
[TBL] [Abstract][Full Text] [Related]
16. Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities: A Multi-Center Retrospective Study.
Batista MV; Ussetti MP; Jiang Y; Neofytos D; Cortez AC; Feriani D; Schmidt-Filho J; França-Silva ILA; Raad I; Hachem R
J Fungi (Basel); 2023 Jan; 9(2):. PubMed ID: 36836281
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis.
Rosanova MT; Bes D; Serrano Aguilar P; Sberna N; Lede R
Infect Dis (Lond); 2018 Jul; 50(7):489-494. PubMed ID: 29262742
[TBL] [Abstract][Full Text] [Related]
18. Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre.
Bowen CD; Tallman GB; Hakki M; Lewis Ⅱ JS
Mycoses; 2019 Aug; 62(8):665-672. PubMed ID: 31050373
[TBL] [Abstract][Full Text] [Related]
19. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience.
Vu CA; Rana MM; Jacobs SE; Saunders-Hao P
Transpl Infect Dis; 2021 Apr; 23(2):e13469. PubMed ID: 32946658
[TBL] [Abstract][Full Text] [Related]
20. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
